Bruker Collaborates with CDC to Advance Infectious Disease Surveillance

BOSTON, June 16, 2016 /PRNewswire/ -- At the American Society for Microbiology (ASM) Microbe 2016 conference, Bruker today announces the results of a successful collaboration with the Special Bacteriology Reference Laboratory at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to create an expanded microorganism reference library for the Bruker MALDI Biotyper.

This new library, encompassing many rare and emerging pathogens, is now searchable through MicrobeNet (https://microbenet.cdc.gov).  Developed by the CDC, MicrobeNet is a database curated by the pathogen subject matter experts and accessible for all public health and clinical laboratories.  The MALDI Biotyper system has been rapidly adopted by microbiology laboratories worldwide as fast and affordable, and as the most comprehensive microbial identification tool available today, replacing conventional biochemical and molecular assays.  The supplementary microbe knowledge base generated by the CDC not only provides expanded capabilities, but access to a wealth of other information and references for MALDI Biotyper users, from different parts of the world, in the global public health arena. It will help researchers identify a wide variety of microbial pathogens more rapidly in order to better serve public health needs.

The MALDI Biotyper is a microorganism species identification system based on specific proteomic fingerprints generated from microbial strains.  It is widely used in microbiology laboratories worldwide due to its proven accuracy, speed and extensive species coverage. The MALDI Biotyper research-use-only (RUO) library contains spectra for over 2,300 species of bacteria and fungi. The MALDI Biotyper (RUO) also supports an open-library concept, enabling users to generate customer-defined and validated libraries to further enhance microorganism coverage.  With the addition of the MicrobeNet MALDI TOF reference library, adding over 800 more species of rare and unusual pathogens, US and international MicrobeNet users now have direct access to the CDC library by sending the MALDI Biotyper data and submitting the search to the CDC MicrobeNet MALDI-TOF library.

John R. McQuiston, Ph.D., Team Lead, Special Bacteriology Reference Laboratory, Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology at the CDC, stated: "Our partnership with the diagnostic testing industry, including Bruker, will lead to greater access to CDC's MicrobeNet system, and dramatically increase the capabilities of the public health community using these instruments."

MicrobeNet was launched in 2013 to help US state public health laboratories and other diagnostic labs rapidly identify rare and emerging infections, with the goal of saving time, money, and lives.  Funded in part by the CDC's Advanced Molecular Detection initiative, MicrobeNet currently includes information about more than 2,400 bacteria and fungi, including images and information about growing these organisms.  Every month, the CDC adds information on as many as 100 new species to MicrobeNet to further extend its utility.

George Goedesky, Vice President for Microbiology at Bruker Daltonics, said: "The public health challenge posed by emerging pathogens is clear and Bruker is committed to leveraging its expertise in MALDI-TOF mass spectrometry to address urgent challenges in the identification of common, as well as of rare and emerging microorganisms.  We are very pleased to have had a long and productive collaboration with the CDC and other public health laboratories on identification of bacteria and fungi using the MALDI Biotyper.  The comprehensive MicrobeNet knowledge base greatly enhances the ability of public health laboratories to respond more quickly to emerging pathogens.  We are honored to partner with the CDC on the MicrobeNet project."

About the Bruker MALDI Biotyper

The MALDI Biotyper family of systems enables molecular identification, and taxonomical classification or de-replication of microorganisms like bacteria, yeasts and fungi.  Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry.  The MALDI Biotyper uses a molecular approach based on specific proteomic fingerprints from bacterial strains and published studies have highlighted the greater accuracy and lower cost offered, as well as the much faster time-to-result (TTR).

Applications of the various MALDI Biotyper solutions include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology.  In many European and international laboratories the MALDI Biotyper has replaced classical biochemical testing for bacterial identification in the past seven years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system.  Classical biochemical techniques detect different metabolic properties of microorganisms, can take many hours or even days for completion, and they often lack specificity. 

The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost.  The products of the MALDI Biotyper family are available in a research-use-only (RUO) version, as the U.S. FDA-cleared MALDI Biotyper CA System, or in an IVD-CE version according to EU directive EC/98/79.  The MALDI Biotyper also has medical device registrations in numerous other countries.  RUO versions of the MALDI Biotyper even allow selected high-value antimicrobial resistance tests in translational research.    

About Bruker Corporation (NASDAQ: BRKR)

For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.  Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. 

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics.  For more information, please visit www.bruker.com.

SOURCE Bruker Corporation

Related Links

https://www.bruker.com